Is VRAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRAX. It does not provide personalized investment advice.

VRAX (Virax Biolabs Group Limited Ordinary Shares) Stock Analysis - Financials

Virax Biolabs Group Limited Ordinary Shares (VRAX) is a publicly traded Healthcare sector company. As of July 9, 2026, VRAX trades at $9.19 with a market cap of $2.42M and a P/E ratio of 0.00. VRAX moved +189.62% today. Year to date, VRAX is -63.22%; over the trailing twelve months it is -85.32%. Its 52-week range spans $2.50 to $80.00. Rallies surfaces VRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are VRAX's key financials?

VRAX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VRAX recently traded at $9.19. Market cap is $2.42M. P/E ratio is 0.00. Revenue is $0.

VRAX Key Metrics

Key financial metrics for VRAX
Metric	Value
Price	$9.19
Market Cap	$2.42M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$80.00
52-Week Low	$2.50
Volume	58.94M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

VRAX Analyst Consensus

VRAX analyst coverage data. Average price target: $0.00.

Common questions about VRAX

What are VRAX's key financials?: VRAX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VRAX recently traded at $9.19. Market cap is $2.42M. P/E ratio is 0.00. Revenue is $0.
Is VRAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRAX. It does not provide personalized investment advice.